Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Regulatory Officer | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IOVANCE BIOTHERAPEUTICS, INC.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 260,842 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 9,766 · Balance 260,842 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 256,364 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Tax withholding · Disposed 4,478 · Balance 256,364 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents the common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 58,599 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 9,766 · Balance 58,599 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents the common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106748 · tm2625111-1_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,599 Underlying: Common stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,478 | $8.70 | $38,958.60 |
DisclosureSEC source: 0001104659-26-106748 · tm2625111-1_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,364 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106748 · tm2625111-1_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105100 · tm2624648-2_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,939 Underlying: Common stock · 5,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,508 | $8.28 | $20,766.24 |
DisclosureSEC source: 0001104659-26-105100 · tm2624648-2_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,076 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105100 · tm2624648-2_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:15 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075854 · tm2618145-1_4seq1.xml · derivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071895 · tm2617137-2_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,365 Underlying: Common stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 3,843 | $4.23 | $16,255.89 |
DisclosureSEC source: 0001104659-26-071895 · tm2617137-2_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,114 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071895 · tm2617137-2_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 5,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070153 · tm2616710-3_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,409 Underlying: Common stock · 5,469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,508 | $3.96 | $9,931.68 |
DisclosureSEC source: 0001104659-26-070153 · tm2616710-3_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,191 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 5,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070153 · tm2616710-3_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 117,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-026451 · tm268453-4_4seq1.xml · derivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,500 Underlying: Common stock · 117,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 39,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024760 · tm268187-2_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,131 Underlying: Common stock · 39,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 18,360 | $4.58 | $84,088.80 |
DisclosureSEC source: 0001104659-26-024760 · tm268187-2_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,230 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 39,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024760 · tm268187-2_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023537 · tm267902-2_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,878 Underlying: Common stock · 5,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,798 | $3.79 | $10,604.42 |
DisclosureSEC source: 0001104659-26-023537 · tm267902-2_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,531 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023537 · tm267902-2_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 5,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118167 · tm2532666-1_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,348 Underlying: Common stock · 5,469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,467 | $2.23 | $5,501.41 |
DisclosureSEC source: 0001104659-25-118167 · tm2532666-1_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,859 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 5,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118167 · tm2532666-1_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087547 · tm2525186-3_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,817 Underlying: Common stock · 5,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,467 | $2.19 | $5,402.73 |
DisclosureSEC source: 0001104659-25-087547 · tm2525186-3_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,857 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087547 · tm2525186-3_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 5,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056444 · tm2517077-5_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,287 Underlying: Common Stock · 5,469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,467 | $1.76 | $4,341.92 |
DisclosureSEC source: 0001104659-25-056444 · tm2517077-5_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,854 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 5,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056444 · tm2517077-5_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| May 23, 2025 Filed May 27, 2025 20:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 5,600 | $1.74 | $9,743.44 |
DisclosureSEC source: 0001104659-25-052968 · tm2516237-1_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,852 F1 · shares: Shares were acquired in the open market during a permitted trading window in accordance with the Issuer's Insider Trading Policy. A copy of the Insider Trading Policy is filed as Exhibit 19.1 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2024. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 00:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-025216 · tm259584-1_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 00:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,509 | $3.59 | $9,007.31 |
DisclosureSEC source: 0001104659-25-025216 · tm259584-1_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,252 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 00:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-025216 · tm259584-1_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 01:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 117,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021871 · tm258333-9_4seq1.xml · derivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,190 Underlying: Common stock · 117,190 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 59,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021056 · tm258333-2_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,756 Underlying: Common stock · 59,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 19,984 | $4.04 | $80,735.36 |
DisclosureSEC source: 0001104659-25-021056 · tm258333-2_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,427 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 59,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021056 · tm258333-2_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 22:15 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129814 · tm2431375-1_4seq1.xml · derivative · entry 3 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,334 Underlying: Common stock · 8,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 22:15 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 3,759 | $7.84 | $29,470.56 |
DisclosureSEC source: 0001104659-24-129814 · tm2431375-1_4seq1.xml · nonDerivative · entry 2 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,412 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 22:15 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129814 · tm2431375-1_4seq1.xml · nonDerivative · entry 1 Puri Raj K. · CIK 0002046483 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.